Upkanz (deferiprone)

Orphan

Region: 🇪🇺 EU
Active substance: deferiprone
Company: Apotex B.V.
Status: Application withdrawn
Therapeutic area: Pantothenate Kinase-Associated Neurodegeneration
Designations: Orphan
Application: EMEA/H/C/005004
ATC: V03AC02
Official record: www.ema.europa.eu

Indication

Treatment of neurodegeneration with brain iron accumulation.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

🇪🇺 Ferriprox Authorised · Chiesi Farmaceutici S.p.A.
🇪🇺 Deferiprone Lipomed Authorised · Lipomed GmbH

Follow Upkanz

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.